- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02271126
TEG Anticoagulation Monitoring During ECMO
Prospective Randomized Study Of Anticoagulation Monitoring With Thromboelastography Versus aPTT During Extracorporeal Membrane Oxygenation In Adults
Study Overview
Status
Intervention / Treatment
Detailed Description
Extracorporeal membrane oxygenation (ECMO) is frequently used as a supportive tool in the settings of acute severe respiratory and/or circulatory failure. The presence of the extracorporeal circuit and oxygenator bring along the need to anticoagulate the patients in order to prevent activation of the coagulation cascade that can lead to thrombosis of the artificial surfaces and losses of coagulation factors, fibrinogen and platelets. Despite tight monitoring with different anticoagulation essays bleeding remain the main threat for the patients on ECMO, leaving thrombosis as an anecdotic event.
In our institution, anticoagulation during ECMO is monitored mainly with aPTT ratio in a range of 1.5 to 2 (patient to normal). Recently, the investigators started to match Thromboelastography (TEG) assays to activated Partial Thromboplastin Time (aPTT) and Activated Clotting Time (ACT) routine measurements during ECMO. Data from a preliminary analysis of thirty-two patients show that in nearly half of TEG assays, the R (reaction time) parameter which is sensitive to inhibition of fibrin formation by heparin, was consistently prolonged despite aPTT and ACT were in the normal range. In the same patients the investigators registered high rate of bleeding (nearly 40% of patients suffered from clinically significant bleeding, i.e. bleeding that required heparin dose reduction, blood transfusions or interruption of the extracorporeal support). These findings suggests the possibility that the actual target of aPTT ratio might be overrated.
The purpose of this study is to test safety and feasibility of standardized protocol based on TEG versus current practice (aPTT) to manage anticoagulation during ECMO.
40 consecutive adults patients undergoing ECMO will be randomized in either the TEG-driven anticoagulation group or the aPTT-driven group. Written informed consent will be obtained according to national legislation.
In both groups, when the patient is connected to ECMO, an heparin bolus of 50-70 UI/kg (depending on baseline aPTT value) will be administered followed by a continuous infusion of 18 UI/kg/h started; for the first 12 hours thereafter proper anticoagulation level will be monitored with Activated Clotting Time (ACT, therapeutic range 180-210 seconds, performed every 1 or 2 hours according to the standardized protocol). From the thirteenth hour onwards each group will follow either aPTT monitoring or TEG according to randomization. Every morning in both groups aPTT, TEG, Antithrombin and anti-Factor Xa activity will be assessed.
- aPTT-driven group: aPTT ratio target is 1.5 - 2.0 as for actual clinical practice; frequency of aPTT measurements may vary from a minimum of 3 times per day to a maximum of 6 depending on the standardized protocol. When aPTT value falls well below the desired range an heparin bolus will be administered. When too high, infusion will be stopped for either 30 or 60 minutes.
- TEG-driven group: target range of R parameter at Kaolin activated-TEG (R K-TEG) is 16 - 24 minutes; frequency of TEG assays may vary from a minimum of 3 times per day to a maximum of 6 depending on the standardized protocol. When TEG value falls well below the desired range an heparin bolus will be administered, when is too high infusion will be stopped for either 30 or 60 minutes.
Daily management requires haemoglobin, platelets, PT ratio, D-dimer and fibrinogen to be checked 2 to 3 times daily, and maintained at specific values (Hb > 10 g/dl; PLT > 45.000/mm3; Fibrinogen > 150 mg/dl; Antithrombin activity > 70%; PT ratio > 1.5) with haemocomponents transfusion.
Data from each patient will be collected on a daily basis: laboratory exams, hemodynamic status, transfusions, surgery or invasive interventions, extracorporeal lung performance.
End of the study will be at ECMO discontinuation, after that deep vein thrombosis on patients' cannulation sites will be assessed with doppler ultrasound.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Lombardy
-
Milano, Lombardy, Italy, 20131
- Fondazione IRCCS Ca Granda - Ospedale Maggiore Policlinico
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- All patients that initiate ECMO support for acute respiratory failure at our centre or by our equipe at another centre will be screened for eligibility.
Exclusion Criteria:
- Patients under the age of 18, with proven Heparin-induced Thrombocytopenia or with a platelets count of less than 30.000/mm3 will be excluded from the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TEG
TEG-driven anticoagulation group: Anticoagulation will be monitored by TEG.
Target will be a range of R parameter at Kaolin activated-TEG (R K-TEG) is 16 - 24 seconds; frequency of TEG assays may vary from a minimum of 3 times per day to a maximum of 6 depending on the standardized protocol.
When TEG value falls well below the desired range an heparin bolus will be administered, when is too high infusion will be stopped for either 30 or 60 minutes.
|
anticoagulation monitoring during ECMO will be according to TEG
Other Names:
Anticoagulation provided to patients in ECMO
|
Active Comparator: APTT
APTT-driven anticoagulation group: anticoagulation will be monitored by aPTT.
aPTT ratio target is 1.5 - 2.0 as for actual clinical practice; frequency of aPTT measurements may vary from a minimum of 3 times per day to a maximum of 6 depending on the standardized protocol.
When aPTT value falls well below the desired range an heparin bolus will be administered.
When too high, infusion will be stopped for either 30 or 60 minutes.
|
Anticoagulation provided to patients in ECMO
anticoagulation monitoring during ECMO will be according to aPTT
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety
Time Frame: Two years
|
Safety will be addressed by monitoring the need of blood components, number of serious haemorrhagic events, thrombotic events and numbers of circuit replacement (due to circuit "activation" and characterized by a definite score that will be assessed daily).
|
Two years
|
Feasibility
Time Frame: Two years
|
Heparin dose fluctuations and numbers of violation from the standardized protocol will be registered to assess feasibility.
|
Two years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Mauro Panigada, MD, Fondazione IRCCS Ca Granda - Ospedale Maggiore Policlinico
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 932/2014
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Extracorporeal Membrane Oxygenation Complication
-
UMC UtrechtErasmus Medical Center; Catharina Ziekenhuis Eindhoven; St. Antonius Hospital; Leiden... and other collaboratorsRecruitingExtracorporeal Membrane Oxygenation | Extracorporeal Membrane Oxygenation ComplicationNetherlands
-
Xiaotong HouNot yet recruitingExtracorporeal Membrane Oxygenation ComplicationChina
-
Vanderbilt University Medical CenterRecruiting
-
Renzo Loyaga RendonSpectrum Health Hospitals; Van Andel Research InstituteActive, not recruiting
-
Sydney Local Health DistrictNot yet recruitingExtracorporeal Membrane Oxygenation ComplicationAustralia
-
Eurosets S.r.l.RecruitingExtracorporeal Membrane Oxygenation ComplicationAustria
-
Australian and New Zealand Intensive Care Research...National Health and Medical Research Council, Australia; Monash UniversityRecruitingExtracorporeal Membrane Oxygenation ComplicationAustralia
-
Second Affiliated Hospital, School of Medicine,...The Second Affiliated Hospital of Jiaxing University; Changxing People's Hospital and other collaboratorsRecruitingExtracorporeal Membrane Oxygenation ComplicationChina
-
University Hospital, ToulouseUnknownExtracorporeal Membrane Oxygenation ComplicationFrance
-
Xiaotong HouNot yet recruitingExtracorporeal Membrane Oxygenation ComplicationChina
Clinical Trials on TEG monitoring
-
The University of Texas Health Science Center,...CompletedIschemic Stroke | Brain HemorrhageUnited States
-
University of Colorado, DenverHaemonetics CorporationRecruitingColorectal Cancer | Esophageal Cancer | Lung Adenocarcinoma | Pancreas Cancer | Liver Cancer | Biliary Cancer | ControlUnited States
-
Hvidovre University HospitalRigshospitalet, DenmarkCompletedBlood Loss | Hip FractureDenmark
-
Washington University School of MedicineOrthopedic Research and Education FoundationTerminatedNeuromuscular ScoliosisUnited States
-
Brigham and Women's HospitalUnknownMesothelioma | CoagulopathyUnited States
-
Stanford UniversityCompleted
-
Institute of Liver and Biliary Sciences, IndiaCompleted
-
Xuanwu Hospital, BeijingPeking University People's Hospital; Chinese PLA General HospitalUnknownCerebrovascular DiseaseChina
-
Stephen EsperAmerican Heart AssociationCompletedHeart Disease | Lung DiseaseUnited States
-
Indiana UniversityRecruitingCoagulopathyUnited States